罗格列酮治疗2型糖尿病合并脂肪肝疗效观察

The effects of rosiglitazone in treatment of type 2 diabetes mellitus-complicated fatty liver

对2型糖尿病(T2DM)合并脂肪肝的患者122例,分成RSG治疗组和对照组。观察6个月。RSG治疗组在改善脂肪肝程度、降低空腹胰岛素及改善肝功能等方面明显优于对照组。

122 patients with type 2 diabetes mellitus-complicated fatty liver were assigned to two groups： the study group with rosiglitazone （RSG） treatment and the control group without rosiglitazone treatment. The change in fatty liver of the patients in both groups were recorded and compared. Based on six months observation, ;the patients with RSG treatment showed a significant improvement as compared with the control group in terms of reduction of fatty liver, reduction of fasting insulin （Fins）and improvement of liver functions.